Amneal names Allergan vet president

Amneal Pharmaceuticals and Impax Labs have new leadership. The Bridgewater, N.J.-based Amneal has named Robert Stewart president, effective Jan. 25, 2018. Stewart was most recently COO at Allergan.

Once Amneal’s acquisition of Impax closes, Stewart will become president and CEO of the combined Amneal Pharmaceuticals, the company said. Also after the close, Impax president and CEO Paul Bisaro will be named executive chairman, with current Amneal co-CEOs and co-founders Chirag Patel and Chintu Patel assuming the titles of co-chairmen of the combined company’s board of directors.

“We are excited that Rob will be joining Amneal. He is a great leader to inspire our team as we prepare for the expected combination with Impax and next phase of our growth in becoming a leading, affordable, healthcare company” Chirag Patel said.

Stewart will work with Chirag and Chintu Patel to lead the company’s current business, as well as play a key role in overseeing pre-integration planning for the planned Impax combination, expected to closein the first half of 2018.

“I am honored and excited to work with the Amneal and Impax teams,” Stewart said. “The combination creates a dynamic leader in generics and specialty pharmaceuticals, with a deep and rich pipeline of products and integrated global manufacturing platform for strong continued profitable growth. I look forward to leading the teams and helping the organization achieve its long-term goals.”

Stewart joined Allergan, which was then Watson, as vice president of global operations in 2009. He held various titles, including president of generics and global operations and president of global operations. Before Allergan, he held various positions at Abbott Labs and Hoffman La-Roche.

“Rob is a highly respected leader with a wealth of pharmaceutical expertise which will further enhance our team of world-class leaders focused on creating value for patients, customers, employees and shareholders,” Chintu Patel said.